- Home
- TRIP vs NVCR Comparison
TRIP vs NVCR Comparison
Compare TRIP & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIP
- NVCR
- Stock Information
- Founded
- TRIP 2000
- NVCR 2000
- Country
- TRIP United States
- NVCR Switzerland
- Employees
- TRIP N/A
- NVCR N/A
- Industry
- TRIP Computer Software: Programming Data Processing
- NVCR Medical/Dental Instruments
- Sector
- TRIP Technology
- NVCR Health Care
- Exchange
- TRIP Nasdaq
- NVCR Nasdaq
- Market Cap
- TRIP 2.0B
- NVCR 2.3B
- IPO Year
- TRIP 2011
- NVCR 2015
- Fundamental
- Price
- TRIP $14.17
- NVCR $17.82
- Analyst Decision
- TRIP Hold
- NVCR Strong Buy
- Analyst Count
- TRIP 14
- NVCR 4
- Target Price
- TRIP $17.86
- NVCR $37.50
- AVG Volume (30 Days)
- TRIP 2.9M
- NVCR 795.3K
- Earning Date
- TRIP 05-07-2025
- NVCR 05-01-2025
- Dividend Yield
- TRIP N/A
- NVCR N/A
- EPS Growth
- TRIP N/A
- NVCR N/A
- EPS
- TRIP 0.04
- NVCR N/A
- Revenue
- TRIP $1,835,000,000.00
- NVCR $605,220,000.00
- Revenue This Year
- TRIP $7.74
- NVCR $3.41
- Revenue Next Year
- TRIP $7.49
- NVCR $9.24
- P/E Ratio
- TRIP $392.35
- NVCR N/A
- Revenue Growth
- TRIP 2.63
- NVCR 18.82
- 52 Week Low
- TRIP $12.93
- NVCR $11.70
- 52 Week High
- TRIP $28.64
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- TRIP 41.88
- NVCR 33.96
- Support Level
- TRIP $14.64
- NVCR $18.23
- Resistance Level
- TRIP $15.46
- NVCR $19.06
- Average True Range (ATR)
- TRIP 0.51
- NVCR 0.80
- MACD
- TRIP 0.08
- NVCR 0.02
- Stochastic Oscillator
- TRIP 38.57
- NVCR 5.57
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.